HERON THERAPEUTICS, INC. /DE/
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
HRTX$0.37+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(18,606) | $(17,241) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 9,237 | 8,160 |
| Depreciation and amortization | 1,372 | 1,777 |
| Amortization of debt discount and debt issuance costs | 734 | 613 |
| Accretion of discount on short-term investments | (403) | (650) |
| Retirement and impairment of property and equipment | 349 | 409 |
| Loss on extinguishment of debt | — | 11,339 |
| Change in operating assets and liabilities: | ||
| Accounts receivable | 2,852 | (2,166) |
| Inventory | (1,587) | (16,865) |
| Prepaid expenses and other assets | 1,921 | (4,550) |
| Accounts payable | (619) | 308 |
| Accrued clinical and manufacturing liabilities | (3,072) | (5,787) |
| Accrued payroll and employee related liabilities | (434) | (806) |
| Other accrued expenses | 3,709 | 7,052 |
| Net cash used in operating activities | (4,547) | (18,407) |
| Investing activities: | ||
| Purchases of short-term investments | (33,898) | (38,214) |
| Maturities and sales of short-term investments | 40,419 | 59,914 |
| Purchases of property and equipment | (631) | (317) |
| Proceeds from sale of property and equipment | — | 82 |
| Net cash provided by investing activities | 5,890 | 21,465 |
| Financing activities: | ||
| Principal and end of term fee payment for notes payable | (18,358) | — |
| Proceeds from the sale of common stock | — | 19,838 |
| Cash paid for issuance costs of stock | — | (1,531) |
| Proceeds from sale of Series A convertible preferred stock | — | 7,862 |
| Cash paid for 2026 Convertible Notes extinguishment | — | (125,000) |
| Cash paid for notes payable extinguishment | — | (25,000) |
| Proceeds from 2031 Convertible Notes issuance | — | 33,250 |
| Cash paid for 2031 Convertible Notes debt issuance costs | — | (1,386) |
| Proceeds from notes payable issuance | — | 108,787 |
| Cash paid for notes payable debt issuance cost | — | (3,406) |
| (Payments) receipts for stock issued under the equity incentive plan | (262) | 207 |
| Proceeds from purchases under the employee stock purchase plan | 225 | 587 |
| Net cash (used in) provided by financing activities | (18,395) | 14,208 |
| Net (decrease) increase in cash and cash equivalents | (17,052) | 17,266 |
| Cash and cash equivalents at beginning of period | 28,647 | 25,802 |
| Cash and cash equivalents at end of period | $11,595 | $43,068 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid | $7,971 | $3,862 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $5,695 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.